Whitehouse Station, NJ, United States of America

Ruben Alberto Tommasi

This inventor holds 19 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 8 EPO patents, primarily in Infectious Disease Treatment. Top assignees: Novartis Ag, Entasis Therapeutics, Inc., Pharmacia & Upjohn Company. Active years: 1998-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ruben Alberto Tommasi. Retrieved from https://idiyas.com/inventor/ruben-alberto-tommasi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 1)

% Patents Active = 73.7

CIPO Patents = 1

EPO Patents = 8 (Patent Applications = 6)

Average Co-Inventor Count = 5.1

ph-index = 6

Forward Citations = 120(Granted Patents)

Location History:

Whitehouse Station, NJ (US) (1998 - 2013)
Cambridge, MA (US) (2012 - 2014)
Waltham, MA (US) (2018)
Stow, MA (US) (2012 - 2021)

Company Filing History:

Entasis Therapeutics, Inc.

patents

3 out of 523

Pharmacia & Upjohn Company

patents

4. 1 out of 834,570

Other

patents

Years Active: 1998-2021

Loading Chart...

Areas of Expertise:

Beta-Lactamase Inhibitors

Matrix Metalloprotease Inhibitors

Cysteine Cathepsin Inhibitors

Combination Therapy

Antibiotic Compounds

Retroviral Infections

HIV Treatment

ArylSulfonamide Compounds

Selective Hydroxamic Acids

Peptidyl Nitriles

Microflow Splitter

Tetronic Acids

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11046694 - Compounds and methods for treating bacterial infections (2021-06-29),

2. 10800778 - Beta-lactamase inhibitor compounds (2020-10-13),

3. 10376499 - Combination therapy for treatment of resistant bacterial infections (2019-08-13),

4. 9968593 - Combination therapy for treatment of resistant bacterial infections (2018-05-15),

5. 9822092 - ArylSulfonamide-based matrix metalloprotease inhibitors (2017-11-21),

6. 8975439 - Arylsulfonamide based matrix metalloprotease inhibitors (2015-03-10),

7. 8841291 - Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors (2014-09-23),

8. 8476286 - Quinazoline derivatives which promote the release of parathyroid hormone (2013-07-02),

9. 8362063 - Arylsulfonamide based matrix metalloprotease inhibitors (2013-01-29),

10. 8314148 - Selective hydroxamate based MMP inhibitors (2012-11-20),

11. 8232427 - Selective hydroxamate based MMP inhibitors (2012-07-31),

12. 8222424 - Arylsulfonamide-based matrix metalloprotease inhibitors (2012-07-17),

13. 6812237 - N-substituted peptidyl nitriles as cysteine cathepsin inhibitors (2004-11-02),

14. 6353017 - Dipeptide nitriles (2002-03-05),

15. 6289914 - Microflow splitter (2001-09-18),

Title: Ruben Alberto Tommasi: Innovator in Antibacterial Compounds

Introduction

Ruben Alberto Tommasi, based in Whitehouse Station, NJ, is a noteworthy inventor with a remarkable portfolio of 19 patents. His innovative work primarily focuses on combating bacterial infections through various pharmaceutical compounds and methods.

Latest Patents

Among his latest innovations, Tommasi has developed several significant patents. One of them is titled "Compounds and methods for treating bacterial infections," which introduces antibacterial compounds represented by a specific chemical formula, providing effective pharmaceutical compositions. Additionally, he has contributed a patent for "Beta-lactamase inhibitor compounds," targeted at developing compounds to inhibit beta-lactamase, a critical element for enhancing the efficacy of beta-lactam antibiotics against resistant bacterial infections.

Career Highlights

Tommasi's professional journey includes vital roles at leading pharmaceutical companies such as Novartis AG and Entasis Therapeutics, Inc. His experience in these organizations has equipped him with valuable insights into drug development and patent creation.

Collaborations

Throughout his career, Ruben Alberto Tommasi has collaborated with notable professionals in the field, including Leslie Wighton McQuire and Olivier Rogel. These partnerships highlight the importance of teamwork in advancing innovations in healthcare.

Conclusion

In summary, Ruben Alberto Tommasi stands out as a significant contributor to the field of pharmaceutical innovations. His extensive patent portfolio and experience in reputable companies underscore his dedication to developing effective treatments for bacterial infections, making a lasting impact in the medicinal landscape.

Profile summary based on public USPTO records.